Advertisement

Follicle-Stimulating Hormone

  • Tom Sam
  • Renato de Leeuw
  • Gijs Verheijden
  • Anneke Koole
Chapter

Abstract

About 15 % of all couples experience infertility at some time during their reproductive lives. Nowadays, infertility can be treated by the use of assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). A common element of these programs is the treatment with follicle-stimulating hormone (FSH) to increase the number of oocytes retrievable for the IVF or ICSI procedure (multifollicular development). Patients suffering from female infertility because of chronic anovulation may also be treated with FSH, then with the aim to achieve monofollicular development.

Keywords

Luteinizing Hormone Assisted Reproductive Technology Chinese Hamster Ovary Cell Line Prefilled Syringe International Nonproprietary Name 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol Hum Reprod 2:361–369PubMedCrossRefGoogle Scholar
  2. Devroey P, Boostanfar R, Koper NP, Jzerman PI, Mannaerts BMJL, Fauser BC, for the ENGAGE Investigators (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24:3063–3072Google Scholar
  3. European Public Assessment Report Gonal-F (Follitropin alpha), CPMP/415/95, revision 18, 11-April 2011. European Agency for the Evaluation of Medicinal ProductsGoogle Scholar
  4. Fauser BCJM, Mannaerts BMJL, Devroey P, Leader A, Boime I, Baird DT (2009) Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 15:309–321PubMedCrossRefGoogle Scholar
  5. Fauser BCJM, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BMJL (2010) Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during controlled ovarian stimulation for in vitro fertilisation. Reprod Biomed Online 21:593–601PubMedCrossRefGoogle Scholar
  6. Howles CM (1996) Genetic engineering of human FSH (Gonal-F®). Hum Reprod Update 2:172–191PubMedCrossRefGoogle Scholar
  7. Mannaerts BMJL, De Leeuw R, Geelen J, Van Ravenstein A, Van Wezenbeek P, Schuurs A, Kloosterboer L (1992) Comparative in vitro and in vivo studies on the biological properties of recombinant human follicle stimulating hormone. Endocrinology 129:2623–2630CrossRefGoogle Scholar
  8. Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I (1990) The biological role of the carboxy-terminal extension of human chorionic gonadotropin (corrected) beta-subunit. Endocrinology 126:376–383PubMedCrossRefGoogle Scholar
  9. Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, Mannaerts B (2011) Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 26(8):2200–2208PubMedCrossRefGoogle Scholar
  10. Olijve W, de Boer W, Mulders JWM, van Wezenbeek PMGF (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (PuregonR). Mol Hum Reprod 2:371–382PubMedCrossRefGoogle Scholar
  11. Van Wezenbeek P, Draaier J, Van Meel F, Olyve W (1990) Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line. In: Crommelin DJA, Schellekens H (eds) From clone to clinic developments in biotherapy, vol I. Kluwer, Dordrecht, pp 245–251CrossRefGoogle Scholar
  12. Verbost P, Sloot WN, Rose UM, de Leeuw R, Hanssen RGJM, Verheijden GFM (2011) Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 651:227–233PubMedCrossRefGoogle Scholar
  13. Voortman G, van de Post J, Schoemaker RC, van Gerwen J (1999) Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injector and syringe. Hum Reprod 14:1698–1702PubMedCrossRefGoogle Scholar

Further Reading

  1. Mannaerts BMJL (2013) Innovative drug development for infertility therapy, Ph.D. thesis, Utrecht, The Netherlands, ISBN 978-90-393-5939-6Google Scholar
  2. Seyhan A, Ata B (2011) The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 3:243–255PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Tom Sam
    • 1
  • Renato de Leeuw
    • 2
  • Gijs Verheijden
    • 3
  • Anneke Koole
    • 4
  1. 1.Regulatory Affairs DepartmentMSDOssThe Netherlands
  2. 2.Regulatory Affairs DepartmentMSDOssThe Netherlands
  3. 3.Synthon Biopharmaceuticals B.V.NijmegenThe Netherlands
  4. 4.Global CMC Regulatory Affairs – Biologics, MSDOssThe Netherlands

Personalised recommendations